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Both low Blood glucose and 
insufficient Treatment confer risk of 
neurodevelopmental impairment in 
congenital hyperinsulinism:  
a Multinational cohort study
Annett Helleskov1, Maria Melikyan2, Evgenia Globa3, Inna Shcherderkina4, Fani Poertner1, 
Anna-Maria Larsen1, Karen Filipsen1, Klaus Brusgaard5, Charlotte Dahl Christiansen1, 
Lars Kjaersgaard Hansen1 and Henrik T. Christesen1*
1 Hans Christian Andersen Children’s Hospital, Odense, Denmark, 2 Pediatric, Endocrinology Scientific Centre, Russian 
Academy of Science, Moscow, Russia, 3 Pediatric Endocrinology, Ukrainian Centre of Endocrine Surgery, Kyiv, Ukraine, 
4 Pediatric, Endocrinology Scientific Centre, Moscow, Russia, 5 Clinical Genetic Department, Odense University Hospital, 
Odense, Denmark
Background/aims: Congenital hyperinsulinism (CHI) is a heterogeneous disease most 
frequently caused by KATP-channel (ABCC8 and KCNJ11) mutations, with neonatal or 
later onset, variable severity, and with focal or diffuse pancreatic involvement as the two 
major histological types. CHI confers a high risk of neurological impairment; however, 
sparsely studied in larger patient series. We assessed the neurodevelopmental outcome 
in children with CHI at follow-up in a mixed international cohort.
Methods: In two hyperinsulinism expert centers, 75 CHI patients were included 
(Russian, n = 33, referred non-Scandinavian, treated in Denmark n = 27, Scandinavian, 
n = 15). Hospital files were reviewed. At follow-up, neurodevelopmental impairment and 
neurodevelopmental, cognitive and motor function scores were assessed.
results: Median (range) age at follow-up was 3.7  years (3.3  months–18.2  years). 
Neurodevelopmental impairment was seen in 35 (47%). Impairment was associated 
with abnormal brain magnetic resonance imaging (MRI); odds ratio (OR) (95% CI) 15.0 
(3.0–74.3), p = 0.001; lowest recorded blood glucose ≤1 mmol/L; OR 3.8 (1.3–11.3), 
p = 0.015, being non-Scandinavian patient, OR 3.8 (1.2–11.9), p = 0.023; and treatment 
delay from first symptom to expert center >5 days; OR 4.0 (1.0–16.6), trend p = 0.05. In 
multivariate analysis (n = 31) for early predictors with exclusion of brain MRI, treatment 
delay from first symptom to expert center >5 days conferred a significantly increased 
risk of neurodevelopment impairment, adjusted OR (aOR) 15.6 (1.6–146.7), p = 0.016, 
while lowest blood glucose ≤1  mmol/L had a trend toward increased risk, aOR 3.5 
(1.1–14.3), p =  0.058. No associations for early vs. late disease onset, KATP-channel 
mutations, disease severity, focal vs. diffuse disease, or age at follow-up were seen in 
uni- or multivariate analysis.
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conclusion: Not only very low blood glucose, but also insufficient treatment as 
expressed by delay until expert center hospitalization, increased the risk of neurodevel-
opmental impairment. This novel finding calls for improvements in spread of knowledge 
about CHI among health-care personnel and rapid contact with an expert CHI center on 
suspicion of CHI.
Keywords: congenital hyperinsulinism, hypoglycemia, neurodevelopmental impairment, neurological outcome, 
treatment delay
inTrODUcTiOn
Congenital hyperinsulinism (CHI) is a heterogeneous disease 
characterized by inappropriate hypersecretion of insulin from 
pancreatic islet β-cells resulting in hypoketotic hypoglycemia 
(1, 2). The incidence is estimated to 1:40,000–50,000 (3–5). 
Although rare, CHI is the most common form of persistent 
hypoglycemia of infancy and the most difficult to manage (6).
Mutations in at least ten genes have been identified to cause 
CHI (ABCC8, KCNJ11, GLUD1, GCK, HADH1, UCP2, HNF4A, 
HNF1A, SLC16A1, PHOX2B), most commonly in ABCC8 or 
KCNJ11 expressing the two subunits of the pancreatic β-cell KATP-
channel, the sulfonylurea receptor 1, and the potassium inward 
rectifier 6.2 (Kir6.2) (7–11).
Focal CHI occurs in approximately 40% and is defined as 
a restricted pancreatic area with adenomatous β-cell hyperplasia, 
resulting in a lesion composed of confluent islet of Langerhans 
(9, 12). Focal CHI is strongly associated with a heterozygous, 
paternally inherited KATP-channel germline mutation combined 
with a focal loss of heterozygosity on chromosome 11p15 with 
loss of maternally expressed tumor suppressors, ABCC8 and 
KCNJ11 (2). 18F-DOPA PET/CT scan is the preferred method 
for preoperative localization of the focal lesion (13).
Diffuse CHI involves β-cells throughout the pancreas and is 
histologically characterized by hypertrophy of a few β-cells per 
islet. Recessive inactivating mutations in ABCC8 and KCNJ11 
are the most common causes of medically unresponsive diffuse 
CHI, whereas dominantly inherited ABCC8/KCNJ11 mutations 
typically are medical responsive (2, 14). First line medical treat-
ment after iv glucose and/or glucagon rescue is the KATP agonist 
diazoxide with the somatostatin analog octreotide as second line 
(15). Rapamycin, an mTOR inhibitor, has more recently been 
used with variable effect (16, 17).
The primary treatment goals are to increase and maintain 
blood glucose concentration above 3.5, or 3.9, mmol/L, depend-
ing on the reference (10). Although heterogeneous in phenotype, 
CHI often presents in the first days of life with severe and 
persistent hypoglycemia, representing a severe threat especially 
for brain metabolism. Furthermore, the elevated serum insulin 
level results in suppression of ketones bodies, which usually 
serve as alternative fuel to the brain in the absence of glucose 
(2, 18, 19) As glucose is required for the rapid growth of the 
brain, neonates and infants with CHI are especially susceptible to 
hypoglycemic damage (20, 21). Hypoglycemic convulsions and 
loss of consciousness are frequent and may be recurrent if not 
treated sufficiently. Abnormal neurodevelopment outcome has 
previously been reported in children with CHI, especially motor 
and speech delay in early childhood (22–30), but also epilepsy, 
visual impairment, and infantile spasms have been reported (31). 
Abnormal neurodevelopmental outcome has also been described 
for children with transient hyperinsulinism, comparable to per-
sistent hyperinsulinism (32, 33).
It could be hoped that the increased recognition in the litera-
ture of CHI as a high-risk condition for brain damage has led to a 
higher prevalence of intact neurodevelopmental outcome today. 
However, systematic cohort follow-up studies of the neurodevel-
opmental outcome are sparse (27, 32, 34), especially studies that 
have clinically testing and neuro-pediatric assessments.
We, therefore, aimed to evaluate the neurodevelopmental 
outcomes for CHI patients from Scandinavia, Russia, and Eastern 
Europe including formal testing of cognitive development and 
motor function when possible.
MaTerials anD MeThODs
An international cohort of children diagnosed with CHI was 
established in collaboration between the Endocrinology Scientific 
Centre, Russian Academy of Science, Moscow, Russia, and Hans 
Christian Andersen Children’s Hospital, Odense University 
Hospital, Denmark, the latter institution also treating patients 
from other Scandinavian countries, Eastern Europe, and Russia.
The cohort consisted of Scandinavian children, diagnosed, 
treated, and assessed at follow-up in Denmark at Hans Christian 
Andersen Children’s Hospital, Odense University Hospital; 
children from Russia who were diagnosed, treated, and assessed 
at follow-up in Russia, Endocrinology Scientific Centre, Russian 
Academy of Science, Moscow; and non-Scandinavians referred 
from Eastern Europe countries or Russia for further treatment in 
Denmark. The patients were treated according to international 
recommendations but with local variations in expertise (expert 
referral centers/local hospitals), drug availability, and preference. 
18F-Fluoro-DOPA PET/CT was only performed in Odense, 
Denmark, in the period studied. Patients were recruited in the 
4-year period January 2013 to December 2016.
The inclusion criteria were persistent (>1  month) CHI 
with inappropriately elevated p-insulin concentrations during 
hypoglycemia, defined as blood glucose below 2.5  mmol/L 
(age ≤3  days), or below 3.2  mmol/L (age >3  days). Exclusion 
criteria were prematurity [gestational age (GA) <32 weeks] and 
severe asphyxia.
From the hospital files, the following data were extracted: GA 
(weeks + days), birth weight, umbilical cord blood pH, and base 
excess, Apgar score at 1 and 5 min, age at first recorded hypogly-
cemia episode, blood glucose values and simultaneous beta cell 
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peptides, maximal glucose infusion rate, age at CHI diagnosis, 
age at treatment start at a local hospital and at a CHI expert center, 
medical and surgical treatment, genetic investigations (rapid 
KATP-channel analysis; if negative followed by analysis of other 
CHI-related genes or next generation sequencing panel for nine 
known CHI genes), and 18F-Fluoro-DOPA PET/CT results.
Note was made of the treatment delay (in days) from first 
hypoglycemic sign to first hospital admission, and from first 
symptom to a CHI expert center. Neurological data were 
extracted from the hospital files including hypoglycemic seizures, 
electroencephalography (EEG) reports, diagnoses of epilepsy, 
head circumference (defining microcephaly <−2SD), blindness, 
hearing loss, cerebral palsy, neuropsychological development by 
clinical investigation, and magnetic resonance imaging (MRI) of 
the brain. In Odense University Hospital, all neurological inves-
tigations since 2011, except hearing and eye examination, were 
performed per protocol and not by indication. The latest reported 
data were used when appropriate.
After data collection, the children were categorized into severe 
or moderate disease. Severe CHI was a priori defined with one 
of the following criteria; maximal intravenous glucose >10 mL/
kg/min; one or more episodes of hypoglycemia ≤1.0 mmol/L; or 
homozygous, compound heterozygous, or paternal heterozygous 
KATP-channel pathogenic mutations with no indication of domi-
nant disease. If none of the above parameters were satisfied, the 
patients were categorized non-severe CHI.
Congenital hyperinsulinism was categorized as early onset 
when the first suspected hypoglycemic symptoms occurred 
<30 days of age; late onset >30 days.
Our cerebral clinical outcomes at follow-up included 
neurological examination by an expert pediatric neurologist, 
Bayley Scales of Infant and Toddler Development 3rd Edition 
(Bayley-III), Developmental Profile 3 (DP-3), Movement 
Assessment Battery for Children 2 (Movement ABC-2), and 
Wechsler’s Intelligence Scale for Children fourth edition 
(WISC-IV) when possible and appropriate. In addition to the 
follow-up investigations of CHI patients, we included Danish 
healthy siblings as controls when possible.
Pediatric neurologists, two physiotherapists, and a child 
psychologist performed the assessments. Bayley-III was used 
to assess fine and gross motor function, language (receptive 
and expressive), cognitive, and adaptive development at ages 
1–42 months. The Russian children tested by a Russian pediatric 
neurologist tested all Bayley items. In Denmark, a child physi-
otherapist tested motor function only. Raw scores of successfully 
completed items were converted to scale scores and to composite 
scores (mean of 100) and transformed to a percentile score with 
a mean of 50.
Developmental Profile 3 was used for assessment of children in 
Russia from 2 to 6 years of age. DP-3 includes 180 items grouped 
into scores on adaptive behavior, social–emotional behavior, 
cognitive function, and communication. Scaled scores were 
transformed to mean standard scores. A DP-3 standard score of 
100 is average and <70 denotes delayed development. A pediatric 
neurologist interviewed the parents to obtain this assessment.
Motor function was evaluated using Movement ABC-2. This 
test is suitable for examining 4–12  year-old children’s skills in 
three core areas: fine motor function, gross motor skills, and 
static/dynamic balance. The test provides a raw score and stand-
ard score, which is transformed to a percentile score with a mean 
of 50.
Cognitive function was evaluated in Danish children using 
WISC-IV, of which all 10 core subtests were administered. The 
full-scale IQ score and 4 index scores were derived (verbal 
comprehension, perceptual organization, processing speed, 
and working memory). These scales have population means 
of 100 and SDs of 15. WISC-IV is appropriate from the age of 
6–16 years, 11 months. A single-blinded pediatric psychologist 
with experience in examining children conducted the WISC-IV 
testing and scoring.
After testing, the patients were categorized as with normal 
neurological development, e.g., Bayley-III or Movement ABC-2 
≥5 percentile, DP-3 score ≥70, or WISC-IV developmental 
quotient ≥70; or with neurodevelopmental impairment, e.g., 
Bayley-III or Movement ABC-2 score <5 percentile, DP-3 score 
<70, WISC-IV score <70, blindness, cerebral palsy, or epilepsy. 
Children who were not able to complete the testing due to severe 
neurological sequela, such as major intellectual disability or major 
motor impairment, were categorized to the neurodevelopmental 
impairment group.
statistical Methods
Means were compared using an independent-sample t-test or 
Mann–Whitney, Mantel–Haenszel, or Fisher’s Exact test were 
appropriate. A p-value <0.05 was considered as statistical 
significant and a trend was considered for p-values 0.05–0.10. 
The association between potential predictive values and mild 
or severe neurodevelopmental impairment was analyzed. 
Covariates included lowest blood glucose value, treatment delay 
from first symptoms to admission at a local hospital or to an 
expert CHI center (analyzed as categorical values after search 
for optimal cut-offs), focal vs. diffuse, and CHI disease severity. 
Univariable regression analysis was followed by multivariable, 
backward logistic regression models to obtain adjusted odds 
ratios (aORs) for associations. Data were analyzed using Stata 
(StataCorp, College Station, TX, USA).
ethics
The study was conducted according to the Helsinki Declaration. 
The Regional Committees on Health Research Ethics for Southern 
Denmark approved the study, protocol number S-20120119 and 
by the local Ethical Committee at the Endocrine Research Center 
of the Ministry of Health Care in Russian Federation.
Written informed consent was obtained from the parents/legal 
guardians of all research participants. The data were approved by 
the Danish Data Protection Agency (13/11991).
resUlTs
The study included 75 children with CHI, Scandinavian group; 
n = 15, referred non-Scandinavians; n = 27, Russian group; n = 33. 
In non-Scandinavians, GA and disease severity were higher, and 
age at follow-up was lower, compared to Scandinavians, Table 1. 
In total, mean (SD) GA was 38 (2.3) weeks; birth weight 3,553 
TaBle 1 | Patient characteristics.
Total scandinaviana referred non-scandinavianb russianc p-valuee
Number of patients n = 75 n = 15 n = 27 n = 33
Birth weight gram, mean ± SD 3,553 ± 730 3,244 ± 586 3,634 ± 787 3530 ± 715 0.13
Gestational age, week, mean ± SD 38 ± 2.3 36 ± 1.0 39 ± 2.3 38 ± 2.1 0.02
Lowest blood glucose, mmol/L, mean ± SD 1.1 ± 0.55 1.2 ± 0.9 0.89 ± 0.6 1.1 ± 0.5 0.17
Glucose infusion rate, mg/kg/min, mean ± SD 10.8 ± 6.6 10.8 ± 6.2 11.0 ± 6.8 N/A 0.75
Early onset <30 days, n (%) 50 (67%) 10 (67%) 22 (81%) 18 (55%) 0.18
Late onset >30 days, n (%) 25 (35%) 5 (33%) 5 (19%) 15 (45%)
Age at follow up, median (range), days 750 (46; 6,660) 2,160 (529; 5,400) 278 (46; 6,660) 765 (120; 2,940) 0.00
Severity of disease 0.00
Severe diseased, n (%) 53 (72%) 8 (53%) 23 (85%) 23 (70%)
Non-severe disease, n (%) 22 (28%) 7 (47%) 4 (15%) 10 (30)%
Genetic mutations, number of patients n = 67 n = 12 n = 27 n = 28 0.054f
ABCC8, n (%) 32 (48%) 5 (42%) 16 (59%) 11 (39)%
KCNJ11, n (%) 7 (10%) 0 (0%) 4 (15%) 3 (11%)
GCK, n (%) 0 (0%) 0 (0%) 0 (0%) 0 (0%)
GLUD1, n (%) 5 (8%) 1 (8%) 1 (4%) 3 (11%)
HNF1A, n (%) 0 (0%) 0 (0%) 0 (0%) 0 (0%) 
HNF4A, n (%) 1 (1%) 1 (8%) 0 (0%) 0 (0%)
11p15 uniparental disomy (BWS), n (%) 1 (1%) 1 (8%) 0 (0%) 0 (0%)
No mutations detected 21 (32%) 4 (34%) 6 (22%) 11 (39%)
Medication at follow-up
Diazoxide n = 44 n = 4 n = 9 n = 31
mg/kg/day, mean ± SD 10.8 ± 8.7 23.4 ± 4.4 11.3 ± 4.5 9.2 ± 6.5
Octreotide n = 16 n = 1 n = 11 n = 4
mcg/kg/day, mean ± SD 11.8 ± 5 14.6 11.0 ± 5.7 13.5 ± 3.2
Sandostatin LAR, number of patients n = 2 n = 1 n = 1 n = 0
Sirolimus, number of patients n = 1 n = 0 n = 0 n = 1
Treatment delay, from first symptom to n = 55 n = 7 n = 23 n = 25
Public hospital, median in days; range 3 (0; 780) 0 (0) 0 (0; 180) 30 (0; 780) 0.18
Expert center, median in days; range 11 (0; 2,519) 0 (0; 341) 33 (0; 572) 240 (28; 2,519) 0.10
18F DOPA PET/CT scan, n n = 40 n = 10 n = 25 n = 5
Focal, n (%) 15 (38%) 2 (20%) 13 (52%) 0 (0%)
Diffuse, n (%) 25 (62%) 8 (80%) 12 (48%) 5 (100%)
Surgery, n n = 75 n = 15 n = 27 n = 33
Restricted focal surgery, n (%) 15 (19%) 2 (13%) 13 (48%) 0 (0%)
Pancreatic resection, partial or subtotal, n (%) 10 (14%) 5 (33%) 3 (11%) 2 (6%)
No surgery, n (%) 50 (67%) 8 (53%) 11 (41%) 31 (94%)
aChildren born, treated and tested in Scandinavia (One child is Danish citizen but was born in Singapore).
bChildren from Eastern Europe/Russia treated in Denmark (Belarus, Kazakhstan, Syria and Ukraine).
cChildren from Russia tested and treated in Russia.
dSevere disease: hypoglycemia ≤1.0 mmol/L; glucose infusion rate >10 mL/kg/min, or KATP-channel mutations with compound heterozygosity,  
homozygosity, non-dominant paternal heterozygosity. BWS, Beckwith–Wiedemann syndrome.
eScandinavian vs. non-Scandinavian.
fKATP-channel defect vs. others.
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(730) g. The median (range) onset of first symptoms was ** 
(**-**) days. Early onset CHI (<1 months) was seen in 50 (67%; 
median ** days) and late onset in 25 (33%; median ** days). The 
mean (SD) lowest recorded blood glucose for the total cohort 
was 0.9 (0.7) mmol/L. Genetic analysis was performed in n = 67 
patients and KATP-channel mutations were identified in 58%, most 
frequently in non-Scandinavians, trend p =  0.054. No genetic 
variations were found in 32% of investigated patients. Medical 
treatment at last hospital contact included diazoxide (n =  44), 
octreotide (n = 16), long-acting release octreotide (n = 2), and 
mTOR inhibitor (n =  1). Forty (54%) children underwent an 
18F-DOPA PET/CT scan, of which 15 (38%) had a focal CHI 
diagnosis by scan. All 15 patients with a focal CHI by 18F-DOPA 
PET/CT had restricted focal surgery with histology-confirmed 
focal lesion and were normoglycemic after surgery.
By clinical examination, six patients (8%) had microcephaly. 
Abnormal EEG was seen in 13 out of 55 (24%). MRI of the brain 
was performed in 40, of which in 19 (47.5%) had abnormal find-
ings. White matter changes (hypoglycemic encephalopathy) was 
seen in 11 (27.5%) and cerebral atrophy in nine (22.5%) as the 
most frequent findings, Table  2. Infarctions were seen in two 
patients, probably after prolonged convulsions.
Follow-up investigations
The median age for the study group at the time of follow up was 
3.7 years (range 3.3 months to 18.2 years). At the clinical follow-up, 
TaBle 2 | Brain magnetic resonance imaging (MRI) findings in children with 
congenital hyperinsulinism.
number Percentage
Total 40
Normal MRI 21 52.5
Abnormal MRIa 19 47.5
Cerebral atrophy
Generalized 9 22.5
Localized 0
Infarction 5
Unilateral 2 5
Bilateral 0
Intracerebral hemorrhage 0
White matter changes 11 27.5
Occipital 1 2.5
Parieto-occipital 5 12.5
Periventricular 1 2.5
Generalized 4 10
aFour patients had more than one abnormality.
TaBle 3 | Clinical neurological outcome for children with congenital 
hyperinsulinism.
Total scandinaviana referred non-
scandinavianb
russianc
Cerebral palsy, n = 75 10 (13%) 1 (7%) 6 (18%) 3 (11%)
Visual impairment, n = 75  4 (5%) 0 (0%) 1 (4%) 3 (11%)
Epilepsy, n = 75 17 (23%) 2 (13%) 6 (18%) 9 (33%)
Microcephaly, n = 39 6 (15%) 1 (7%) 5 (15%) N/A
Electroencephalography, 
n = 55
Normal 42 (76%) 3 (75%) 16 (48%) 23 (85%)
Abnormal 13 (24%) 1 (25%) 6 (18%) 6 (22%)
MRI of the brain, n = 40
Normal 21 (53%) 5 (33%) 11 (33%) 5 (19%)
General atrophy 9 (23%) 1 (7%) 7 (21%) 1 (4%)
White matter changesd 11 (28%) 1 (7%) 8 (24%) 2 (7%)
aChildren born, treated and tested in Scandinavia.
bChildren from Eastern Europe/Russia, tested and further treated in Denmark.
cChildren from Russia, tested and treated in Russia.
dReduced myelinization or hypoglycemic encephalopathy.
TaBle 4 | Bayley-III, Developmental Profile 3 and Movement ABC-2 test results 
for children with congenital hyperinsulinism.
russiana referred non-
scandinavianb
scandinavianc
Bayley-III, mean ± SD, 
percentiles
n = 13 n = 27 n = 3
Cognitive 20.3 ± 31.6
Communication 13.1 ± 20.3
Motor 29.0 ± 31.5 27.1 ± 31.0 50.0 ± 0
Social-emotion 23.4 ± 32.9
Adaptive 15.6 ± 33.9
Developmental Profile 3, 
mean ± SD, score
n = 20
Physical 75.6 ± 26.5
Adaptive 77.6 ± 28.1
Social 75.3 ± 28.6
Cognitive 70.5 ± 26.0
Communication 73.5 ± 25.6
Total score 68.2 ± 31.4
Movement ABC-2, 
mean ± SD, percentiles
n = 12
Fine motor 32 ± 37
Gross motor 52 ± 39
Balance 38 ± 29
Total 37 ± 35
aChildren from Russia, tested and treated in Russia.
bChildren born in Eastern Europe/Russia, tested and further treated in Denmark.
cChildren born, treated, and tested in Scandinavia.
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impairment. For communication, social–emotional behavior and 
adaptive behavior, mean (SD) percentile varied from 13 (20.3) to 
23.4 (32.9). Based on all available Bayley-III data, 18 (42) were 
categorized as with neurodevelopmental impairment.
Developmental Profile 3
In the DP-3 test performed in Moscow in 20 children, mean 
(SD) full-scale score was 68 (31), which denoted to below 
average. Eight children (40%) were categorized as normally 
developed with a mean (SD) of 100 (23.8). Twelve children 
(60%) had a DP-3 score below 70 denoting neurodevelopmen-
tal impairment. Of these, nine had a score <50 denoting severe 
neurodevelopmental delay. The sub-items physical, adaptive, 
communication, cognitive, and social profile had a mean (SD) 
score from 77 (28) to 70 (26).
Movement aBc-2
Age-standardized motor function percentiles in the Danish 
patients aged >6  years could be compared to sibling controls 
(n = 5), thereby reducing the impact of parental factors. A sig-
nificantly lower mean total motor function was observed in the 
CHI group, 38 ± 35 vs. 78 ± 35 percentile, p = 0.047, Table 5. 
This was driven by a significant lower balance function for the 
CHI patients, 38 ± 29 vs. 72 ± 26 percentile (p = 0.03), and to 
a less degree a reduced fine motor function, 32 ± 37 vs. 65 ± 34 
percentile (trend p = 0.10). No significant difference was seen in 
gross motor function. Two children had a total motor function 
<5 p that denoted to the neurodevelopmental impairment group 
and two children had low normal total motor function score 
equaling 5–15 p.
10 patients (14%) had cerebral palsy, Table 3. Epilepsy was seen in 
15 (20%), of which one was diagnosed with infantile spasms. Four 
(5%) had severe visual impairment; none had diagnosed hearing 
loss. Twenty-three (31%) had severe developmental delay based 
on clinical neurological examination. In total, 35 (41%) were 
categorized with severe neurodevelopmental impairment based 
on the above parameters.
Bayley scales of infant and Toddler 
Development
In the Bayley-III test, mean (SD) total motor function in 43 infants 
equaled the 29.5 (30) percentile, Table 4. The majority (n = 23, 
58%) had a normal motor function ≥5 percentile with a mean 
(SD) of 53.4 (21.3) percentile. Fifteen (35%) were categorized 
as impaired by total motor score with a mean (SD) of 0.9 (1.4) 
percentile.
Mean (SD) cognitive Bayley-III score was 20 (31.6) in 13 infants, 
of which four had a mean <5 p denoting neurodevelopmental 
TaBle 5 | Cognitive score and motor function for children with congenital hyperinsulinism above 6 years of age and healthy siblings as controls.
Patient  
1/sibling
Patient  
2  
(sibling)
Patient  
3  
(sibling)
Patient 
4
Patient 
5
Patient 
6
Patient  
7 
(sibling)
Patient 
8
Patient 
9
Patient 
10
Patient 
11
Patient 
13
Wisc-iV score
Verbal comprehension index 99/110 97/99 122/118 91 99
Perceptual organization index 79/120 101/105 122/111 96 109
Working memory index 60/134 83/77 83/86 92 116
Processing speed index 92/130 110/144 101/121 87 84
Total score 79/126 96/106 112/112 89 101
Movement aBc, percentile
Fine motor 5/95 84/75 1/63 5 84 37/84 5/9 8 5 63 25 99
Gross motor 2/84 75/95 9/75 16 95 84/95 5/25 91 5 98 84 75
Balance 37/91 91/91 91/91 9 50 37/50 16/37 63 37 50 16 25
Total 5/98 91/95 9/84 5 91 50/95 1/16 63 10 63 25 75
WISC-IV: Wechsler’s Intelligence Scale for Children fourth edition.
TaBle 6 | Overall neurodevelopmental outcome for children with congenital 
hyperinsulinism (CHI) by patient data.
normal 
development
neurodevelopmental 
impairment
Geography and center category 40 (53%) 35 (47%)
Scandinavians 12 (80%) 3 (20%)
Eastern Europeans 12 (44%) 15 (56%)
Russians 16 (36%) 17 (52%)
Onset
Early onset 24 (48%) 26 (54%)
Late onset 16 (64%) 9 (36%)
Medical delay from first symptom
≤2 days 19 (61%) 12 (39%)
>2 days 21 (48%) 23 (52%)
Medical expert delay from first 
symptom
≤5 days 12 (80%) 3 (20%)
>5 days 28 (47%) 32 (53%)
Lowest blood glucose
Blood glucose ≤1 mmol/L 10 (33%) 20 (67%)
Blood glucose >1 mmol/L 30 (67%) 15 (33%)
Severity of disease
Non-severe CHI 15 (68%) 7 (32%)
Severe CHI 25 (47%) 28 (53%)
Genetics
KATP-channel mutations 17 (44%) 22 (56%)
Other gene mutations 6 (86%) 1 (14%)
No mutations detected 11 (52%) 10 (48%)
18F-DOPA PET/CT scan
Focal 6 (40%) 9 (60%)
Diffuse 14 (56%) 11 (44%)
N/A 21 (60%) 14 (40%)
Magnetic resonance imaging brain
Normal 16 (76%) 5 (24%)
Abnormal 3 (16%) 16 (84%)
N/A 21 (60%) 14 (40%)
Age at follow-up
Age ≤810 days 18 (50%) 18 (50%)
Age >810 days 22 (56%) 17 (44%)
Normal development: WISC-IV score >70, Bayley-III or Movement ABC-2 >15 
percentile, or DP-3 score >70. Neurodevelopmental impairment: WISC-IV score 
<50, Bayley-III or movement ABC-2 <5 percentile, Developmental Profile 3 score 
<50, epilepsy, cerebral palsy, visual impairment, or too retarded to  
complete testing.
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Wisc-iV
Cognition was assessed by use of WISC-IV for five patients, of 
which three had a healthy sibling tested for control, Table 5. The 
mean (SD) full-scale score for the five patients were 95.6 (12.4) 
with a range of 79–112.
For the three tested sibling-pairs, a trend toward a nine score 
lower mean was observed for the CHI patients, 95  ±  12 vs. 
114 ± 10 (p = 0.066). This trend was driven by a difference in 
the processing speed, 80 ± 14 vs. 131 ± 7, p = 0.054. All CHI 
children were on basis of this assessment denoted to the normally 
developed group.
Overall Outcome
The overall neurodevelopmental outcome is listed in Table 6. Of 
our total cohort, 47% (n = 35) had neurodevelopmental impair-
ment. Low normal function by Bayley-III or movement ABC-2 
equaling 5–15 percentile was detected in six (8%).
Split by nations, 20% of the Scandinavian patients had 
neurodevelopmental impairment, whereas 52% of the Russian 
patients, and 56% of the non-Scandinavian patients referred to 
Denmark were severely impaired. All six children with micro-
cephaly were denoted to the neurodevelopmental impairment 
group. All of those belonging to the normally developed group 
had a normal EEG, whereas 45% of those with neurodevelop-
mental impairment had an abnormal EEG. Three children with 
occipital hypoglycemic encephalopathy by MRI scan showed 
normal development at follow-up.
In univariable analysis, neurodevelopmental impairment 
was associated with abnormal MRI of the brain; OR (95% CI) 
15.0 (3.0–74.3), p =  0.001, non-Scandinavian patient, OR 3.8 
(1.2–11.9), p =  0.023; treatment delay from first symptom to 
expert center >5  days; OR 4.0 (1.0–16.6), trend p =  0.05, and 
lowest blood glucose ≤1 mmol/L; OR 3.8 (1.3–11.3), p = 0.015, 
Tables 6 and 7. Patients with KATP-channel mutations and focal 
disease had marginal trends only toward higher odds of impair-
ment. No associations were detected for early vs. late disease 
onset, disease severity, delay from first symptom to first treat-
ment, or age at follow-up.
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In the multivariable analysis, only 31 patients could be 
included due to missing data. In Model 1, only MRI of the brain 
remained associated to neurodevelopmental impairment, aOR 
(95% CI) 16.8 (2.3–123.3), p = 0.005, while “expert delay” had a 
trend toward increased risk, OR 4.4 (0.7–28.4), p = 0.12. When 
analyzing associations to early predictors only by exclusion of 
age at follow-up and MRI of the brain (Model 2), delay from 
first symptom to expert center treatment significantly associated 
with neurological impairment, aOR 15.6 (1.6–146.7), p = 0.016, 
whereas lowest blood glucose ≤1  mmol/L conferred a trend 
toward increased risk, aOR 3.5 (0.9–12.7), p = 0.058.
DiscUssiOn
In our mixed international cohort of children with CHI, 47% of 
the patients had neurodevelopmental impairment at follow-up, 
despite huge advances in knowledge about CHI. Univariable 
factors associated with neurodevelopmental impairment were 
delayed from first symptom to expert treatment center (trend), 
lowest recorded blood glucose ≤1.0 mmol/L, non-Scandinavian 
patient, and abnormal MRI of the brain. By multivariable 
regression analysis, excluding brain MRI, “expert delay” became 
significantly associated, while lowest recorded blood glucose 
≤1.0 mmol/L showed a trend toward increased risk. Compared 
to siblings, motor function and cognitive score were lower in a 
small subset of Danish patients.
Neonatal hypoglycemia is a well-known cause of neurodevel-
opmental impairment, depending on the hypoglycemia severity, 
duration, and comorbid factors (35–38). Neonatal hypoglycemia 
is, however, usually transient and predictable by perinatal risk 
factors, which confers opportunities for prevention and early 
management (39). Early detection and adequate treatment of tran-
sient neonatal hypoglycemia are associated with an un-increased 
risk of adverse neurological outcome (37), or lower fine motor 
function in boys and a higher internalizing score in girls, both 
within the normal range at school age follow-up. Other follow-up 
studies report of increased adjusted odds for developmental delay 
in late preterms with blood glucose <1.1 mmol/L (40), adverse 
neurodevelopmental outcome in diabetic mothers’ term neonates 
with neonatal blood glucose 0.0–1.5 mmol/L at 7–8 years’ follow-
up (41), and lower school performance at 10  years after early 
transient hypoglycemia (<2.5 mmol/L < 3 h of age) in preterm 
and term neonates (42).
In CHI, an alarmingly high prevalence of neurodevelopmental 
delay, epilepsy, seizures, blindness, and microcephaly have been 
reported in other studies (22–24, 31, 34, 43–46). Of note, even 
children with transient CHI had a 30% risk of abnormal neu-
rodevelopment in a recent UK study (32), with onset <7 days of 
age and disease severity defined by diazoxide dose as predictive 
factors. Other studies of various size and outcomes have shown 
a risk of adverse neurological outcome in CHI up to 50% (22, 
26–28, 30, 34, 46–48).
Of larger follow-up studies, neurodevelopmental retarda-
tion was found in 44% of 114 CHI patients in Germany (23), 
psychomotor retardation in 26% of 90 patients in France (22), 
neurological deficits in 45% of 65 CHI patients in Australia (48), 
and neurodevelopmental delay in 18% of 43 Saudi Arabian CHI 
patients (47). Despite the huge improvements in knowledge and 
management possibilities in CHI, our multinational patient 
cohort showed no improvement in neurodevelopmental outcome 
compared to the former studies.
We also found that motor function, especially balance and fine 
motor function, and cognitive score were lower, although still in 
normal range, in a small subset of Danish patients compared to 
their siblings. Similar findings were seen in follow-up of Danish 
children with transient neonatal hypoglycemia (unpublished 
data). This indicate that even apparently normal functioning 
children with CHI should be fine-tested at follow-up, as some 
could benefit from interventions to improve especially balance 
and fine motor function.
In our study, abnormal MRI of the brain strongly associated to 
neurodevelopmental impairment, also in the multivariable analy-
sis. Hypoglycemia of any kind in the neonatal period or infancy 
is associated to abnormal MRI findings, especially white matter 
TaBle 7 | Logistic regression for factors associated to neurodevelopmental impairment in congenital hyperinsulinism (CHI) patients.
Univariate regression Multivariate regression
Factors crude Or (95% ci) p-value a(Or) Model 1 
n = 31
p-value a(Or) Model 2 
n = 31
p-value
Non-Scandinavian vs. Scandinavian, n = 75 3.8 (1.2–11.9) 0.023
Early vs. late onset, n = 75a 1.0 (0.4–2.8) 0.97
Medical delay >2 vs. ≤2 days, n = 56 1.5 (0.5–4.4) 0.42
Expert delay >5 vs. ≤5 days, n = 56 4.0 (1.0–16.6) 0.050 4.4 (0.7–28.4) 0.12 15.6 (1.6–146.7) 0.016
Lowest blood glucose ≤1 vs. >1 mmol/L, n = 63 3.8 (1.3–11.3) 0.015 3.5 (0.9–12.7) 0.058
Severe vs. non-severe CHI, n = 74b 1.6 (0.6–4.1) 0.35
KATP-channel mutations vs. not, n = 68 1.6 (0.2–8.5) 0.11
Focal vs. diffuse disease, n = 39 2.8 (0.7–11.1) 0.13
Magnetic resonance imaging brain normal vs. abnormal, n = 38 15.0 (3.0–74.3) 0.001 16.8 (2.3–123.3) 0.005
Age at follow up, >810 vs. <810 days, n = 74 2.1 (0.62–7.5) 0.22
Model 1 included all factors before stepwise exclusion. Model 2 did not include MRI of the brain and age at follow-up.
OR, odds ratio; a(OR), adjusted odds ratio.
aEarly onset ≤30 days; late onset >30 days.
bSevere CHI: maximal intravenous glucose >10 mL/kg/min, one or more episodes of glucose ≤1 mmol/L, or homozygous, compound heterozygote or paternal, non-dominant 
heterozygous KATP-channel mutations.
Significant or trend p-values in bold.
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changes also known as hypoglycemic encephalopathy (49–51). 
In CHI, posterior (parieto-occipital) white matter changes is 
especially prominent, which relate to timing of hypoglycemia to 
the neonatal period and lack of ketone bodies as alternative fuel 
(51) We also found a high prevalence of posterior white matter 
lesions, but in the most severe, undertreated patients, global 
cerebral atrophy, and intracerebral hemorrhage were seen.
In the Saudi study of 43 patients, only 14 out of 18 patients 
with developmental delay had cerebral atrophy on imaging (47), 
stating that not all with abnormal cerebral imaging will present 
with clinically overt impairment, as also seen in our study.
Among early predictors, recorded blood glucose ≤1.0 mmol/L 
significantly associated with neurodevelopmental impairment. 
In contrast to others (22, 23, 32), we detected no increased 
cerebral risk for early onset CHI, neither when using a cut-off of 
30 days, nor 7 days (data not shown). We believe that untreated 
hypoketotic hypoglycemia is the major direct cause of brain 
damage in CHI. Although the neonatal brain is more susceptible 
to hypoglycemia than in later childhood, early onset may well be 
a proxy for severe hypoglycemia, which is strongly associated to 
early onset, but difficult to extract without information bias in 
a retrospective setting with data from many hospitals in many 
countries, where frequent and systematic blood glucose record-
ings may not have been the rule. Our a priori defined severe CHI 
category did not associate with the neurological outcome. We 
never the less succeeded in detecting an association to adverse 
outcome for lowest recorded blood glucose ≤1.0  mmol/L. 
The definition of severe CHI included an i.v. glucose demand 
>10  mg/kg/min, which we used as an alternative to lowest 
blood glucose <1.0 mmol/L, as the latter criteria was subjected 
to variations in treatment. However, initial i.v. glucose demand 
recordings were often missing and hence recorded if possible at 
follow up before 18F-DOPA PET/CT (performed without other 
medication).
In our mixed cohort, delay until expert center and non-
Scandinavian patient status were also determining factors for 
neurodevelopmental impairment in univariable analysis. This 
was probably due to non-recorded low and/or long hypoglyce-
mic periods in this group of patients. As hypoglycemia should 
be treated promptly and sufficiently, these factors may, therefore, 
reflect insufficient treatment. However, the multivariate analysis 
only had delay until expert center as a significant associated factor. 
This may be explained by a lower study number in the multivari-
ate analysis, but also by the fact that non-Scandinavian patients 
had a higher disease severity than Scandinavians, possibly reflect-
ing selection bias. Considering delay until expert treatment, this 
may also reflect both selection bias and unrecorded insufficient 
treatment (low blood glucose). However, selection bias could be 
bidirectional: Patients with mild CHI may not have been referred 
to an expert center, but on the other hand, some patients with 
very severe disease were referred promptly. This leaves insufficient 
treatment as the major likely explanatory factor. The range of 
documented insufficient treatment was in one non-Scandinavian 
patient 12 months with untreated, very severe CHI, and cerebral 
palsy and severe infantile spasms. The insufficient treatment in 
this patient reflected limited hospital resources and self-payment 
for medical treatment.
In the other end of the spectrum, a Danish term neonate 
was erroneously discharged untreated a few hours after birth 
despite an unmeasurable low blood glucose recording because 
of paucity of symptoms, but readmitted at the age of 2 days with 
loss of consciousness and convulsions and blood glucose of 
0.0 mmol/L. Only 1 week later, this patient was referred to the 
national expert center. Despite adequate treatment from then 
on, this infant also showed neurodevelopmental impairment 
and infantile spasms.
The novel identification of insufficient treatment as a risk 
factor does not call for more knowledge about CHI, but for 
improvements in spread of knowledge about CHI among health 
care personnel, especially rapid contact with an expert CHI center 
on suspicion of CHI.
Already in year 2000, a workshop held by the European net-
work for research into hyperinsulinism (ENRHI) advocated for 
early referral to a multidisciplinary expert center (15). National 
or international referral is nowadays frequent for this rare and 
complex disease with need of experts in 18F-DOPA PET, medi-
cal, and surgical management. However, our findings underscore 
the need of significant improvements in prompt diagnosis and 
adequate treatment of CHI in every birth clinic and hospital, 
as just a very short time without sufficient treatment can cause 
brain damage. Given the rarity and often surprising severity of 
CHI, this task remains a major challenge for health-care provid-
ers dealing with birth clinics, neonatal, and pediatric wards, 
for health-care authorities and for relevant medical societies. 
Education of health-care personnel and popular communication 
should be systematically enforced, potentially in the context 
of hypoglycemia in general. Force task groups should be set to 
develop strategies for the prevention of untreated or undertreated 
CHI. Last, rapid funding is urgently needed in order to avoid 
delay in international referrals when needed.
Limitations of our study included the observational, partially 
retrospective design, selection bias due to referral practice favor-
ing more severely affected patients and those with genetic results 
suggesting focal CHI, and the cohort size, however, relatively large 
for a rare disease. Lack of systematic data included not only brain 
MRI but also initial blood glucose values, continuous glucose 
monitoring, and i.v. glucose demand recordings. The disease sever-
ity assessment was, therefore, subjected to limitations. Follow-up 
was performed at different ages by different investigators using 
different methods, why robust cut offs (normal/abnormal) were 
used for comparisons. At last follow-up, some of the patients had 
relatively low age, where neurodevelopmental adverse outcomes 
may not yet be detectable. Multivariable analyses were hampered 
by missing data and hence a lower study number, and residual 
confounding, including potential unmeasured factors related to 
local differences in our mixed cohort, e.g., socioeconomic factors.
Strengths included our multinational setting, hospital file 
review of blood glucose data, the detailed and systematical 
prospective neurological outcome testing at follow-up, and the 
relatively long median follow-up time.
In conclusion, 47% of our CHI patients had neurodevelopmen-
tal impairment at follow-up, despite huge advances in knowledge 
about CHI. Not only very low blood glucose but also insufficient 
treatment as expressed by delay until expert center hospitalization 
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